Buy & Sell Walmart Stores Inc (WMT) – Walmart Stores Inc Price Today
Aura AI Summary
Key Stats
- $967.20BMarket Cap
- Consumer StaplesSector
- -9.6%3M Drawdown
- $1.03TEnterprise Value
- 0.82%Dividend Yield
- 57% Buy | 43% SellTrading Activity
- 96 daysTypical Hold Time
Walmart Stores Inc (WMT) is currently valued at a market capitalization of $967.20B, with an enterprise value of $1.03T. Over the past 52 weeks, Walmart Stores Inc has traded between a low of $94.25 and a high of $134.2, highlighting its annual price range. Over the past three months, Walmart Stores Inc has recorded a drawdown of -9.6%, reflecting recent price volatility. Walmart Stores Inc offers a dividend yield of 0.82%, with the most recent dividend of $0.25 paid on 08 May 26. On average, investors hold Walmart Stores Inc for approximately 96 days, indicating typical investor behavior on the platform.
About Walmart Stores Inc
Walmart Inc. operates discount stores, supercenters, and neighborhood markets. The Company offers merchandise such as apparel, house wares, small appliances, electronics, musical instruments, books, home improvement, shoes, jewelry, toddler, games, household essentials, pets, pharmaceutical products, party supplies, and automotive tools. Walmart serves customers worldwide.
Most Recent News
ROCKWOOL CFO Kim Junge Andersen vested 6,511 restricted shares under 2023 incentive plan
Kim Junge Andersen, CFO of ROCKWOOL A/S, vested 6,511 restricted share units on May 22, 2026, as part of the company's 2023 long-term incentive scheme. The shares were granted without a purchase price and traded on Nasdaq Copenhagen. This transaction...

CN Energy's Pathenbot launches intelligent robotic cargo sorting in the US with a 100,000-unit order.
CN Energy Group's subsidiary Pathenbot has signed an order to provide intelligent robotic cargo sorting services in the United States, marking the commercial launch of these services. The initial order covers 100,000 units and includes barcode scanni...

BioNTech to present promising late-stage cancer drug data at 2026 ASCO meeting
BioNTech will showcase new clinical data for its late-stage oncology drugs pumitamig and gotistobart at the 2026 ASCO Annual Meeting. Pumitamig showed encouraging anti-tumor activity in first-line non-small cell lung cancer, while gotistobart demonst...
